Hematopoietic stem cell transplantation and protection from disability progression in multiple sclerosis

Autologous hematopoietic stem cell transplantation (AHSCT) resulted in significantly longer time to first incidence of confirmed disability progression compared to other anti-inflammatory disease modifying therapies (DMT; P=0.005).
AHSCT-treated individuals also reported lower Expanded Disability Status Scale scores over a 10-year period and were more likely experience sustained disability improvement (P<0.001) than those treated with anti-inflammatory DMT (P<0.001).
The authors concluded that AHSCT has the potential to slow and potentially reverse disability progression for individuals with active secondary progressive multiple sclerosis.